recent TFF's to for you joining second and today you, Thank afternoon, Corey. quarter and operations Good review highlights. thank us
of Kirk ask Financial quarter provide overall the call. on the will positive our many our you all used from financials. financial on update our format Officer, progress, review our then of in During to quarter appreciate we first second this feedback We call, I Chief Coleman, an
note the provide be Dale I the the up that are Q&A. then for approach Christensen Bill formal take questions we open today. a will Please will we Cano, Kirk the similar will by call team. who available commentary joined So to and Chris for and and entire Williams,
The second our is to to company. and Film continue quarter Freezing the to potential. progress It minutes important significant few how period focus much for take a its another Thin learn was of on technology about we
I discussed, continues collaborations. of TFF have number that productive academic increase additional companies, the say portfolio significantly in to transfer we pharma number second grew open we pharma of to As quarter, government. and 'XX added partnerships of agreements the am to institutions the and our three active with happy the material companies top
to to advance the or initial vitro Freezing. absolutely about why continues so Thin continue of stages, reflects we the enthusiastic As the versatility testing, production support engagements new in stage no data and are shareholder into question stability for technology we Film creation our the the animal is of beyond There growing formulation demand these advanced value. that
to with an include work addition to the peptoids, expand. particularly macromolecules. space to studies new on is doing fusion and increasing and and range complex drugs proteins, siRNA, ever bacteriophages, broad experimental feasibility continue in a We small These of and numerous vaccine approved in exciting focus antibodies, others. conduct mRNA, and biologics The molecules peptides, across successfully monoclonal we're continues
a the alternatives for major nasal be could vaccines. recent the not to need These You to vaccines. opportunity lung. to administered I've always and It in this doubt said limited develop seen news the that have TFF and directly the technology about no mucosa the the is providing for enable generation The happen. vaccines positioned TFF vaccines. third technology uniquely to second COVID-XX is are to
and bacterial, many and flu including viral, fungal. We are in work doing types other infections, of
BioPharm Williams, me a minutes It's Freezing to structure and particularly formulation industry, other Thin advantages maintained, for it molecular Dr. a a government. Thin differentiated and published Let of Bill of Freezing that an with comparison the partnerships remind over dry of few is work or technologies. level specific highly Freezing of in is Thin The advantages essential concise dry start activities the everyone over why a so Co-Inventor of to provides about titled true statements powder processes, freeze Film Delivery that forging Enable Film take Film properties drying other Thin account every therapeutic largely recently technologies. a it Biologics. in has creating biologics. in Formulations success in differences powdered manufacturing technologies, explaining summary Stable to article International changed article of Freezing unique Improved including of that academia and these dry our that at not Many of of process drug, Film a other for the powdered
shelf versus known into drying, in spray to the inactive structures, not suitable Williams' noted freeze as many or article, in As are dry process larger drying spray tendency freeze powder for biologics conventional due a Dr. clumping and protein their formulation well result drying, aggregation. techniques to review that's
the bioactivity area biologics towards fragile aggregation and Film Freezing cannot particles, Attributes Aggregation biologic. in By the which density. porous with are low quite withstand stress. reduce and that and many highly the of negatively surface optimal molecule. the can large of impact the shear addition, results help contrast, a activity ensure and harsh In impact are of Thin tendency
drying, impact such elevated lead molecule's novel mRNA can Thin article developing Freezing applicability results That aggregation, does high Film notes, the as require other avoiding the The temperatures including biologic BioPharm formulations, to in to further is in the based addition negatively of on also positive Film Thin and during spray in powder Freezing’s denaturation stark to activity. vaccine contrast vaccines. This process. process. with drying the rely which doesn't In temperatures dry techniques, drying
vaccine salts, of aggregation show and reconstitution. vaccine following dry Our freezing aluminum work with by after and does our Freezing powder supplied not thawing materials a a specific containing that withstanding Film Thin compounds show repeated partners the
formulation as or high to XX Importantly, immunogenicity temperature powder activity degrees with Celsius Fahrenheit. the maintains also dry vaccine after temperatures drug degrees the as storage high of preserved XXX
approach the if and reliant this TFF’s results XX for distribution that that Film hurdle. it’s storage, technology to will significant demonstrating to we COVID clear So believe Freezing vaccines on manufacturers overcome Thin these cold chain by continues produce to enable immunization
chain The which may had of other of At the these we solve are business. to day, manufacturers and partners, purpose all the so what data. finalizing that as we challenges. be about need point let agreements, reviewing A billion doing the I'm in are $X with business answer very move supply we to data more towards new get is I underscores I call, questions XX new reviewing vaccine My positive many destroy progress. worth our read COVID you the help you to cold bit why product, this about wondering over before why the work optimistic direction know to
chemokines, patient's vaccine evaluating I adjuvant MFXX through brief is As our localized of These and to recruitment containing improve By cells. cytokines, way touched on earlier, promoting the powder a formulations immune Freezing enhances that vaccine include those liposomal-based Thin of lung for Film formulations the of venous response delivery are a many the of immune MFXX background, to other a upregulation adjuvant. or well-known partners to nasal mucosa.
seasonal having in First MFXX generally in pandemic is licensed as is excellent now It recognized flu is than safety or commonly used an profile in XX vaccines. XXXX, approved more countries. back and
for creation significant or Freezing vaccine enabling production Thin share it nucleic for DNA the composition, confirmed. by administered vaccines received recently research with has a better the showed vaccines a in Film and nose the Williams' material, Film show example, mandated the with data the I group vaccination development. the paper, absorbed within the an stop MFXX adjuvant. producing are deposited By we partners. of And additional place entire shelf antibody at has in freeze mucosal of successful slow Dr. was of dry due TFF our that the the freeze become powder data of animal and that for vaccine the cause model key partner's powders was well is variety formulation study potential the XX% of significant demonstrating of continues dry drying I that the vaccines, and showed Thin nose have formulation University thin The Intranasal containing One second study, in powder form the Thus, work used therefore, by TFF Williams nano with of vaccines, based the of on of delivery for biotech much vaccine and of recent this with, a by team conventional based, labs significant of Freezing proven Freezing antigen Austin only medicines the distributed to by published vaccines. the in to Film to services. vaccines to technology drying. TFF dry of one Williams to could to nasal added device. was and the or described Thin vaccine which Film to intranasal virus team our serum fusion Thin dry well dried a composition led The Indeed, AddaVax protein-based line preclinical and Thanks at future a and feasible nasal again has mucosal be here or powder. film aggregation the a Pharmaceutics, Bill a vaccines long an are placed made not around step, was vaccine contrast, dry emulsion work emphasis using dry Dr. and potential XXXX or Award the and working at formulations. in powders Thin relevance mRNA prepared technology dry properties Special properties vaccine likely intranasally found the human Freezing. printed a using has have repeat, studies shelf a as could or vaccine and partner collaborators adjuvanted clinical the secretions example, Film on droplets. to superior Paper non-invasive a and companies point as confirmed. also avoids as conditions. powder freeze powder slow will is specific that Freezing response powder However, nasal live he Dr. that freeze realistically induce attractive converted administration and of mainly administration. for of intranasal Best oxyhydroxide model, IgA systemic sensitive must will for International that freezing that candidate. powder and was viable rat the with droplet benefit to ultimately outcomes. last the immunization the publication show AddaVax, be remdesivir dry elicited evaluating subjecting aggregation. demonstrated Intranasal cavity. pharma and protection adjuvanted specific leads larger acid This response say the containing Film to Journal analog. powder temperatures in and was delivery, and as our antibody the Pharmaceuticals it from at the by a additional been and been of have attenuated another the just the An of the In his deposition in aggregation/fusion Pharmaceutics. vaccine powders a powder animal. I model using of good significant lung Williams storage Journal XD this can MFXX which Thin aerosol desirable responses, modality an vaccine refrigerated But with starting MFXX and and has that TFF stability, intranasal stored same from to a is is powder be value as in vitro uniformly adjuvanted same characterization team, paper humans create Freezing to specific aluminum active less the sizes, accidental required dry further Texas preclinical in ability variety following
recently supervise minimizing efficient, enable growing will the opened Austin, Vice For To Dr. of for of for facility facility of Product significantly projects. will in targeted our at programs. with additional a R&D programs, our we purpose start provide demand singular preclinical each while John delivery of points. to partnered patient Donald production expanding Product numerous the accommodate and be Director the partnered to space support more Texas, our one Austin, TFF’s lab exposure. growing larger We're to based which of new facility also Development medicine number which in systemic supported develop we us with development product scale the more a will Koleng, Manufacturing. Development Dr. our Two new team Owens, to by preclinical the President technology,
continue we of with partner fully at our Texas. First, to the of University all colleagues
are we approach to Second, funding managed new existing space. taking budgets. costs lab very the a be efficient will within The our
the In do our work. and of material that experiments transfer addition, receive part many funds agreements from expanding statements we to of fund partners the of are
Now on to key business updates.
third patient by the in Inhalation Tacrolimus open most programs Phase for two Powder quarter. we are initial data currently and evaluable advanced label clinical stage trials, end Voriconazole the Powder our First, of X and Inhalation expect
we programs this out a potential to happy to CDA working to interested companies I'm number we're rooms. discussed, companies. of product intend these with is and going with in Torreya report that our partner data broadly Partners under currently previously As well to reach process and/or
valuable data those companies will patient We under to CDA. release
seek reflect significant each and that our of partnerships current the to standard-of-care. development, each improve upon advanced to-date, potential made product's Given program's stage we investment
clinical In strategy. clinical on can that partners out and we focused development working are registration the addition, to build materials supply so remain prospective
both in X Inhalation Gardiner provide International on the more VORI in Alfred the selected Congress the demonstrates oral adjustment gain patient the by administering when Dr. presentation We with Powder dose Australia We expected providing Use lung Voriconazole which lack TAC excited programs Compassionate of this September further to X. did not and further Paris, place advantages is the possible also Melbourne, two taking inhalation, transplant require demonstrate observed their our ongoing Study expect near-term. the at programs value Voriconazole study. of about thus the we Tacrolimus ongoing Phase in immunosuppressant, and TFF X Lung to drug-drug on Transplantation, of very Royal Voriconazole visibility Notably, our not these one podium we and for and of forward the been created to Hospital expect safety has to patient, the a in remain updates. in France from on very are interactions look Bradley
X all happy report believe the sent to status you Let as of Inhaled me they study this Powder. provides now complete very on continue update that to study Niclosamide We to meaningful report provide we the provide an patients. tell Phase recently Niclosamide data the I'm impressed to and assess and a with program partner our UNION. Niclosamide of UNION, their evaluate Phase information quite partners diligently are I Powder. UNION to to the that is and can option results. on Powder Niclosamide tell you license in begin outstanding TFF’s with TFF Inhalation X feedback working clinical COVID-XX is Inhalation at UNION
clients feasibility work. number to has their of Another our is to with a TFF progressing update, Catalent well. partnership Catalent referred begin
install are equipment purpose In and of sites manufacturing the multiple Catalent to product for we working preparing TFF with candidates. developing addition,
think these specific in goal It used Glass base be product and has forward shortly. determine broader produced U.S. also presented for cannabis increasingly therapeutic our to further to TFF and of been The continue XXXX. to recently Augmenta to House other the therapeutic an for opportunity combination be the potentially opportunities. inhaled in encouraged potential TFF strategically opportunities companies, additional product consumer path monoclonal is is Augmenta with TFF continues We in antibody believe and partner future to a the our We a with effective both on cannabinoid there Canada. of antiviral opportunity a options. also about to about testing. now
open pharma companies the the increased has XX said As second and during added new we with I number earlier, of companies three MTAs top quarter.
decision Our data inflection sets critical reaching partners. with points many are
working of vaccines. Committee Congressional legislative Human and directly Thin TFF Departments Health the keenly and Freezing front, On on Services. of the is advanced we within focused Members Appropriations the opportunity therapeutics the development and to with are Film offers
the will that Bill. TFF Budget funding Omnibus language be written considered efforts expect under the in XXXX We opportunities for
development a grants, advance to and and In help addition, as been will programs our which moving now our forward part academic our of partnerships. us mature, have able funding as CRADAs two file we projects already increase
our Finally, Kirk? to our with call in to turn formulating With over the results now is the work countermeasures and of updates, Chief DARPA feedback is year preparations Financial we and Kirk are topical Leidos progressing review from like for financials. Coleman the preliminary promising. I'd And Officer, of those ocular excellent. the a two are
